With Local Participation, BRI Poised for Major Type 1 Discoveries
February 2nd, 2010
JDRF awarded Seattle’s Benaroya Research Institute (BRI) a $9.4 million grant to accelerate the study of type 1 diabetes causes and cures last winter. The five-year grant supports the JDRF-BRI Center for Translational Research to transform basic science into clinical trials and medicine. BRI is one of seven JDRF-designated autoimmune diabetes research centers worldwide.
Extensive research has been conducted using animal models—such as the non-obese diabetic (NOD) mouse—and scientists have discovered hundreds of ways to cure diabetes in these animals. The goal is to use this information to improve the lives of people with diabetes.
Using samples from individuals and families with type 1 diabetes, BRI researchers can better evaluate the most promising therapies when tested in human clinical trials.
Over the next few years, BRI scientists will attempt to decode the type 1 autoimmune response—when the immune system attacks insulin cells—and develop therapies to retrain faulty immune systems so they won’t attack healthy tissues. Autoimmunity—stopping or reversing the immune system response that causes type 1 diabetes—is one of JDRF’s five therapeutic goals.
With Local Participation, BRI Poised for Major Type 1 Discoveries
JDRF awarded Seattle’s Benaroya Research Institute (BRI) a $9.4 million grant to accelerate the study of type 1 diabetes causes and cures last winter. The five-year grant supports the JDRF-BRI Center for Translational Research to transform basic science into clinical trials and medicine. BRI is one of seven JDRF-designated autoimmune diabetes research centers worldwide.
BRI research teams will investigate the disease through research and clinical trials integrating genomics, immunology and cell biology. Blood samples from Pacific Northwest residents with type 1 diabetes and their family members are critically needed to speed the pace of this important research.
Extensive research has been conducted using animal models—such as the non-obese diabetic (NOD) mouse—and scientists have discovered hundreds of ways to cure diabetes in these animals. The goal is to use this information to improve the lives of people with diabetes.
Using samples from individuals and families with type 1 diabetes, BRI researchers can better evaluate the most promising therapies when tested in human clinical trials.
Over the next few years, BRI scientists will attempt to decode the type 1 autoimmune response—when the immune system attacks insulin cells—and develop therapies to retrain faulty immune systems so they won’t attack healthy tissues. Autoimmunity—stopping or reversing the immune system response that causes type 1 diabetes—is one of JDRF’s five therapeutic goals.
Blood Samples Needed
Samples from people with type 1 diabetes and their family members are urgently needed to move research forward. A small stipend and parking are provided. Learn more about participating in these BRI studies. Or contact Christine Webber at BRI, 800-888-4187 or diabetes@BenaroyaResearch.org.